Clin2
NCT07227818Likely a fitRecruiting

Testing NBI-1117568 to prevent schizophrenia relapse

Schizophrenia

Treatments studied

Part of Mental health clinical trials.

This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
560 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have been diagnosed with schizophrenia for at least 1 year.
  • You have had a positive response to at least one antipsychotic medicine (not including clozapine).
  • You are generally healthy and do not have unstable medical conditions like uncontrolled heart, liver, or kidney disease.
  • You have not been in a psychiatric hospital for 30 days or more in a row within the last 3 months.
  • You have not started or increased any therapy like counseling or support groups in the last 3 weeks.
  • You have never been treated with clozapine for treatment-resistant psychosis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07105098Recruiting· Phase 3
Study of a new drug for schizophrenia in hospitalized adults

This study tests an experimental drug (NBI-1117568) for people with schizophrenia who are currently in the hospital due to worsening symptoms. Participants stop their current antipsychotic and take the study drug to see if it can help control symptoms.

Culver City, California
NCT06963034Recruiting· Phase 3
Study of a new medicine for adults with schizophrenia

This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.

Bryant, Arkansas
NCT07114874Recruiting· Phase 3
A long-term study of a new drug for schizophrenia

This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.

Bryant, Arkansas
NCT07288333Recruiting· Phase 2
New medication for schizophrenia in hospitalized adults

This study tests an experimental medication (NBI-1117570) for adults with schizophrenia who are currently in the hospital because of a sudden worsening of symptoms. The goal is to see if this new treatment can help control symptoms better.

Kazanlak
NCT07686263Not yet recruiting· Phase 3
Testing a new drug to prevent schizophrenia relapse

This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.

Bentonville, Arkansas
NCT06894212Recruiting· Phase 3
Testing a new med for schizophrenia flare-ups

This trial tests a new medication called SEP-363856 for people with schizophrenia who are currently having a severe flare-up of symptoms. It aims to see if the drug is safe and effective compared to a placebo.

Bentonville, Arkansas

Hear when a new Schizophrenia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.